+Compare
ABEO
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
119.16M

ABEO Abeona Therapeutics Forecast, Technical & Fundamental Analysis

a developer of pharmaceutical products

Industry Biotechnology
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for ABEO with price predictions
07:00 PM EST Dec 07, 2023

ABEO's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for ABEO turned positive on November 24, 2023. Looking at past instances where ABEO's MACD turned positive, the stock continued to rise in of 38 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 24, 2023. You may want to consider a long position or call options on ABEO as a result. In of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

ABEO moved above its 50-day moving average on November 10, 2023 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for ABEO crossed bullishly above the 50-day moving average on November 10, 2023. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ABEO advanced for three days, in of 236 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 107 cases where ABEO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for ABEO moved out of overbought territory on November 29, 2023. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 47 cases where ABEO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABEO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ABEO broke above its upper Bollinger Band on November 27, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ABEO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.574) is normal, around the industry mean (20.733). P/E Ratio (0.113) is within average values for comparable stocks, (137.900). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (7.704). Dividend Yield (0.000) settles around the average of (0.035) among similar stocks. P/S Ratio (25.445) is also within normal values, averaging (330.425).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABEO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sorrento Therapeutics (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.3B. The market cap for tickers in the group ranges from 402 to 464.61B. NVO holds the highest valuation in this group at 464.61B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 10,162%. For the same Industry, the average monthly price growth was 8%, and the average quarterly price growth was 27%. OZYMD experienced the highest price growth at 8,999,901%, while ZVSA experienced the biggest fall at -57%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -10%. For the same stocks of the Industry, the average monthly volume growth was 4% and the average quarterly volume growth was 51%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 62
SMR Rating: 94
Profit Risk Rating: 94
Seasonality Score: 28 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Ad is loading...
A.I. Advisor
published Earnings

ABEO is expected to report earnings to -48 cents per share on March 18

Abeona Therapeutics ABEO Stock Earnings Reports
Q4'23
Est.
$-0.48
Q3'23
Beat
by $0.05
Q2'23
Missed
by $0.25
Q1'23
Est.
$-0.54
Q4'22
Beat
by $0.69
The last earnings report on November 13 showed earnings per share of -47 cents, beating the estimate of -52 cents. With 111.17K shares outstanding, the current market capitalization sits at 119.16M.
A.I. Advisor
published General Information

General Information

a developer of pharmaceutical products

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Generic
Address
1330 Avenue of the Americas
Phone
+1 646 813-4701
Employees
57
Web
https://www.abeonatherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FGDKX52.120.28
+0.54%
Fidelity® Growth Discovery K
TECHX13.840.07
+0.53%
WisdomTree Technology and Inn 100 DgtN/A
IVOIX17.790.06
+0.34%
Delaware Ivy Mid Cap Income Opps I
VCINX10.560.03
+0.28%
VALIC Company I International Growth
AHSZX19.59N/A
N/A
Alger Health Sciences Z

ABEO and

Correlation & Price change

A.I.dvisor tells us that ABEO and AXON have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ABEO and AXON's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABEO
1D Price
Change %
ABEO100%
+0.63%
AXON - ABEO
31%
Poorly correlated
+0.45%
FATE - ABEO
30%
Poorly correlated
-4.68%
PCVX - ABEO
29%
Poorly correlated
-0.19%
NTLA - ABEO
29%
Poorly correlated
-2.55%
CARM - ABEO
28%
Poorly correlated
-1.18%
More

Groups containing ABEO

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABEO
1D Price
Change %
ABEO100%
+0.63%
pharmaceuticals
(undefined stocks)
25%
Poorly correlated
-0.20%
pharmaceuticals generic
(undefined stocks)
19%
Poorly correlated
-0.92%